Analyst consensus rating
Kymera Therapeutics Analyst Rating: Strong Buy
Direct answer
Kymera Therapeutics's consensus rating is Strong Buy.
22 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $134.95.
Forecast evidence checked September 6, 2026.
Get free Kymera Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $117.39
- Average price target
- $134.95
- High price target
- $170.00
- Low price target
- $111.00
- Low target gap
- -5.4%
- Target upside
- +15%
- High target gap
- +44.8%
- Target range width
- 50.3%
- Consensus rating
- Strong Buy
- Analysts
- 22
- Evidence date
- September 6, 2026
- Valid through
- September 13, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kymera Therapeutics?
Kymera Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $134.95.
How far are Kymera Therapeutics's low and high targets from the recorded price?
The low target implies -5.4%, while the high target implies +44.8%.
How many analysts are included in Kymera Therapeutics's consensus?
The verified consensus includes 22 analysts.
How is Kymera Therapeutics's target upside or downside calculated?
The average target of $134.95 is divided by the recorded price of $117.39, then one is subtracted to produce +15%. This does not guarantee a future return.
When was Kymera Therapeutics's analyst forecast verified?
The data was verified on 2026-09-06. The dataset is valid through 2026-09-13.